Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 4/20 | 0.72 |
| ▸ | POLA1 | P09884 | 1/20 | 0.69 |
| ▸ | VDR | P11473 | 3/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.57 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10298005 | 1.00 | CDC25A (0.72) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL6742962 | 1.00 | CDC25A (0.72) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL13412384 | 0.92 | CDC25A (0.67) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL8918931 | 0.92 | CDC25A (0.67) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL8918935 | 0.92 | CDC25A (0.67) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL10425455 | 0.92 | CDC25A (0.66) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL10425289 | 0.90 | CDC25A (0.62) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL11146732 | 0.90 | CDC25A (0.72) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL8837072 | 0.90 | VDR (0.61) | CDC25APOLA1VDRUSP2ST6GAL1 | |
| SCHEMBL14007471 | 0.89 | CDC25A (0.59) | CDC25APOLA1VDRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030157158-A1 | Enhanced liposomal thioretinaco ozonide compositions and liposomal carrier | MCCULLY KILMER S (US) | 2003-08-21 | — | — | US | claimed |
| WO-2003057192-A1 | ENHANCED LIPOSOMAL THIORETINACO OZONIDE COMPOSITIONS AND LIPOSOMAL CARRIER | MCCULLY KILMER S (US) | 2003-07-17 | — | — | WO | claimed |
| US-6696082-B2 | COMPLEX COMPRISING N-HOMOCYSTEINE THIOLACTONYL RETINAMIDE, COBALAMIN, OZONE, OXYGEN, AND ADENOSINE TRIPHOSPHATE; ANTICARCINGENIC, ANTITUMOR, AND VIRICIDAL AGENTS; ATHEROSCLEROSIS PREVENTION; AGING RESISTANCE | MCCULLY KILMER S (US) | 2004-02-24 | — | — | US | disclosed |
| US-20030157158-A1 | Enhanced liposomal thioretinaco ozonide compositions and liposomal carrier | MCCULLY KILMER S (US) | 2003-08-21 | — | — | US | disclosed |
| WO-2003057192-A1 | ENHANCED LIPOSOMAL THIORETINACO OZONIDE COMPOSITIONS AND LIPOSOMAL CARRIER | MCCULLY KILMER S (US) | 2003-07-17 | — | — | WO | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| US-5688780-A | ANTICHOLESTEROL AGENTS, CHOLESTEROL BIOSYNTHESIS INHIBITION | SRI INTERNATIONAL (US) | 1997-11-18 | — | — | US | disclosed |
| US-5510340-A | OXYSTEROL ANALOGS | SRI INTERNATIONAL (US) | 1996-04-23 | — | — | US | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
| US-4684479-A | Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures | CAVITATION-CONTROL TECHNOLOGY, INC. | 1987-08-04 | — | — | US | disclosed |